Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial

  • Richard Greil*
  • , Petra Obrtlíková
  • , Lukáš Smolej
  • , Tomáš Kozák
  • , Michael Steurer
  • , Johannes Andel
  • , Sonja Burgstaller
  • , Eva Mikušková
  • , Liana Gercheva
  • , Thomas Nösslinger
  • , Tomáš Papajík
  • , Miriam Ladická
  • , Michael Girschikofsky
  • , Mikuláš Hrubiško
  • , Ulrich Jäger
  • , Michael Fridrik
  • , Martin Pecherstorfer
  • , Eva Králiková
  • , Cristina Burcoveanu
  • , Emil Spasov
    • Andreas Petzer, Georgi Mihaylov, Julian Raynov, Horst Oexle, August Zabernigg, Emília Flochová, Stanislav Palášthy, Olga Stehlíková, Michael Doubek, Petra Altenhofer, Lisa Pleyer, Thomas Melchardt, Anton Klingler, Jiří Mayer, Alexander Egle
*Korrespondierende:r Autor:in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

48   !!Link opens in a new tab Zitate (Scopus)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial“. Zusammen bilden sie einen einzigartigen Fingerprint.
sortieren

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science